Uncategorized

ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

Published

6 days ago

on

As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog petrelintide.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version